Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of XH-S003 in Healthy Volunteers
NCT05946876Phase 1Completed
- Sponsor
- Fosun Pharma
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing A (XH-S003) with B (Placebo) (2 arms). Primary endpoints: Adverse Events at 7 days and Clinical laboratory abnormalities at 7 days. Started Aug 2023; status: completed.
02
Drugs
XH-S003
Beyond the preview
Go deeper on NCT05946876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05946876.